Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) shot up 46.5% during mid-day trading on Wednesday .The company traded as high as $1.29 and last traded at $1.03. 66,915,194 ...

Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...

Silexion Therapeutics Corp. has announced a strategic partnership with Catalent to advance the development of its RNA interference therapy, SIL204, aimed at treating KRAS-driven cancers.

Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of December 31, 2024 and 2023, 0 and 43,121 shares issued and outstanding as of December 31, 2024 and ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...

“Our expanded development plan reflects the strength of recent preclinical data and our commitment to addressing the complexities of KRAS-driven cancers,” said Ilan Hadar, Chairman and CEO of Silexion ...

SILEXION THERAPEUTICS CORP CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except share data) Year ended December 31 2024 2023 OPERATING EXPENSES: Research and development ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...